Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) traded up 1% during mid-day trading on Tuesday . The stock traded as high as $0.41 and last traded at $0.41. 100 shares were traded during trading, a decline of 88% from the average session volume of 857 shares. The stock had previously closed at $0.41.
Defence Therapeutics Stock Performance
The firm’s fifty day moving average is $0.41 and its 200-day moving average is $0.55.
Defence Therapeutics Company Profile
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Recommended Stories
- Five stocks we like better than Defence Therapeutics
- What is MarketRank™? How to Use it
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- 3 Best Fintech Stocks for a Portfolio Boost
- Netflix Is On Track To Hit $1,000 By Christmas
- What is Insider Trading? What You Can Learn from Insider Trading
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
